University of Leicester Leads Breakthrough in Vascular Gene Research

Researchers from the University of Leicester's Division of Cardiovascular Sciences have published a landmark study in Nature Communications that pinpoints specific genes in blood vessel cells as potential new targets for treating heart disease and other vascular conditions. This work, conducted within the National Institute for Health Research Leicester Biomedical Research Centre and the British Heart Foundation Leicester Centre of Research Excellence, integrates functional genomics to bridge the gap between genetic associations and actionable therapeutic insights. By focusing on vascular smooth muscle cells (VSMCs)—the key structural components of blood vessel walls—the team has illuminated how genetic variants contribute to diseases like coronary artery disease (CAD), hypertension, stroke, and abdominal aortic aneurysm (AAA).

The study represents a pinnacle of collaborative higher education research in the UK, where interdisciplinary teams at Leicester have leveraged advanced genomic tools to decode complex disease mechanisms. This not only advances scientific understanding but also underscores the vital role of UK universities in translating basic research into clinical hope for millions affected by cardiovascular issues.

The Growing Burden of Vascular Diseases in the UK

Cardiovascular diseases remain the leading cause of death in the United Kingdom, claiming around 110,000 lives annually—one death every five minutes. Over 7.6 million people live with heart and circulatory conditions, with coronary artery disease affecting approximately 1.9 million individuals in England alone as of recent general practice records. Hypertension impacts millions more, while conditions like stroke and AAA add to the toll, straining the National Health Service (NHS) and the economy through lost productivity and treatment costs exceeding billions yearly.

In this context, UK higher education institutions like the University of Leicester are at the forefront, driving research that promises to alleviate this crisis. Genome-wide association studies (GWAS) have identified hundreds of genetic loci linked to these diseases, but pinpointing the causal genes has proven challenging. Leicester's study addresses this head-on, offering a roadmap for precision medicine tailored to vascular health.

Methodology: A Comprehensive Functional Genomics Approach

The Leicester team generated a vast expression quantitative trait loci (eQTL) catalogue from 1,486 umbilical cord-derived VSMCs, genotyping and sequencing RNA to map how genetic variants influence gene expression in these critical cells. They compiled tagging single nucleotide polymorphisms (SNPs) from large-scale GWAS on CAD, hypertension, stroke, and AAA, then applied colocalization tools like eCAVIAR and SMR/HEIDI to nominate 134 causal genes for CAD, 74 for hypertension, 13 for stroke, and 43 for AAA.

Further layers included ATAC-seq for open chromatin, DNA methylation profiling, and H3K27ac HiChIP-seq to validate regulatory elements. Pooled CRISPR knockout screens tested these genes' impact on VSMC proliferation and migration—hallmarks of vascular pathology. Targeted follow-up with siRNA knockdown and in vivo mouse models provided rigorous validation, particularly for the gene FES, blending human genetics with experimental biology in a gold-standard pipeline.

Key Causal Genes and Pleiotropic Discoveries

Among the highlights, 18 genes emerged as pleiotropic, influencing multiple vascular diseases. Notable examples include:

• FES: Linked to both CAD and hypertension, modulating vascular remodeling pathways.
• BCAR1 and SMARCA4: Shared between CAD and AAA, affecting VSMC behavior.
• ARNTL, CSNK2B: CAD-hypertension overlap.
• CARF, PROCR: CAD-stroke connections.

Gene ontology analysis revealed enriched pathways like TGFβ signaling in CAD, VEGF signaling in hypertension, and VEGFR/PDGFR/integrin pathways in AAA. About 60% of disease-associated SNPs showed eQTL effects in VSMCs, underscoring their central role in vascular pathology.

FES: From Genetic Hit to Functional Culprit

FES, a non-receptor tyrosine kinase, stood out as a prime candidate. CRISPR screens showed FES knockout boosts VSMC migration without altering proliferation. RNA-seq and proteomics on FES-knockdown cells revealed upregulated genes in extracellular matrix remodeling, including matrix metalloproteinases (MMP1/3), promoting vessel instability.

Gene set enrichment highlighted inflammation, fibrosis, and atherosclerosis signatures. In human validation using UK Biobank PheWAS, FES variants correlated with CAD, hypertension, and related traits, cementing its causal role across diseases.

Mouse Models Confirm Atherosclerosis and Hypertension Links

To test in vivo relevance, researchers crossed Fes-knockout mice with Apoe-/- (atherosclerosis-prone) models. Results showed significantly larger aortic root lesions (P=0.013), indicating accelerated plaque buildup. Blood pressure measurements revealed elevated systolic and diastolic pressures (P=0.042), with impaired acetylcholine-induced vasodilation (P=0.027/0.014), mimicking human vascular dysfunction.

These findings validate FES as a bidirectional regulator: loss promotes disease, suggesting gain-of-function or inhibitors as therapeutic strategies. This rigorous translation from human genetics to animal physiology exemplifies Leicester's research excellence.

Druggable Targets: A Pipeline for New Therapies

Strikingly, 63 CAD targets, 39 hypertension targets, and others are potentially druggable, with 38 encoding proteins already targeted by existing drugs. Pleiotropic genes like FES offer 'two-for-one' potential, addressing multiple conditions simultaneously. For more details on the study, visit the full paper here.

UK Biobank and BHF data further support these targets' relevance. BHF statistics highlight the urgency: with CVD causing one in six UK deaths, genetically validated targets could revolutionize drug development, improving success rates from the typical 10%.

Leicester's Ecosystem for Cardiovascular Excellence

The University of Leicester's prowess stems from its integrated infrastructure: the NIHR BRC funds clinical translation, while the BHF Centre fosters basic discovery. Lead investigators like Professor Shu Ye and Professor Nilesh J. Samani, with decades of GWAS leadership, helm teams blending genomics, cell biology, and pharmacology.

This study builds on prior Leicester triumphs, such as CAD locus fine-mapping, positioning the university as a UK hub for vascular genetics. Collaborations with Oxford (e.g., Gillian Douglas) amplify impact, showcasing higher education's collaborative power.

Impact on UK Higher Education and Research Landscape

Amid funding challenges, Leicester exemplifies how targeted investments yield global breakthroughs. NIHR and BHF grants sustain PhD training and postdocs, nurturing talent. This research informs policy, like UKRI priorities for precision medicine, and boosts Leicester's rankings in cardiovascular sciences.

Broader UK unis like Oxford, Cambridge, and Edinburgh contribute complementary vascular studies, forming a national network. For BHF CVD overview, see their factsheet.

Career Pathways in Cardiovascular Genetics

This study opens doors for researchers: roles in genomics labs, CRISPR screening, and mouse modeling abound at Leicester and beyond. UK unis seek experts in VSMC biology, with demand rising for drug discovery specialists. PhDs via BRC programs lead to postdocs, lecturer positions, and industry pharma roles.

• Skills: GWAS analysis, single-cell eQTL, CRISPR editing.
• Opportunities: NIHR fellowships, BHF grants.
• Salary outlook: Lecturer £45k+, Professor £70k+.

Future Outlook: From Bench to Bedside

Challenges remain: neonatal VSMCs may not fully mirror adult pathology; cell-type specificity needs refinement. Yet, pleiotropic druggables like FES herald multi-disease therapies, potentially slashing UK CVD burden. Ongoing trials and AI integration promise acceleration, with Leicester poised to lead.

Stakeholders—patients, policymakers, academics—must champion funding. This Leicester triumph inspires UK higher ed to pursue bold genomics, fostering healthier futures.

Photo by Nastia Petruk on Unsplash